Cook JD - Search Results

1

Bayesian design of single-arm phase II clinical trials with continuous monitoring.

Johnson VE, Cook JD. Johnson VE, et al. Among authors: cook jd. Clin Trials. 2009 Jun;6(3):217-26. doi: 10.1177/1740774509105221. Clin Trials. 2009. PMID: 19528131

2

Accounting for patient heterogeneity in phase II clinical trials.

Wathen JK, Thall PF, Cook JD, Estey EH. Wathen JK, et al. Among authors: cook jd. Stat Med. 2008 Jul 10;27(15):2802-15. doi: 10.1002/sim.3109. Stat Med. 2008. PMID: 17948869 Free PMC article.

3

Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Li Y, Bekele BN, Ji Y, Cook JD. Li Y, et al. Among authors: cook jd. Stat Med. 2008 Oct 30;27(24):4895-913. doi: 10.1002/sim.3329. Stat Med. 2008. PMID: 18563789 Free PMC article.

4

Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.

Thall PF, Cook JD, Estey EH. Thall PF, et al. Among authors: cook jd. J Biopharm Stat. 2006;16(5):623-38. doi: 10.1080/10543400600860394. J Biopharm Stat. 2006. PMID: 17037262

5

Dose-finding based on efficacy-toxicity trade-offs.

Thall PF, Cook JD. Thall PF, et al. Among authors: cook jd. Biometrics. 2004 Sep;60(3):684-93. doi: 10.1111/j.0006-341X.2004.00218.x. Biometrics. 2004. PMID: 15339291

6

Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomization.

Du Y, Cook JD, Lee JJ. Du Y, et al. Among authors: cook jd. J Biopharm Stat. 2018;28(2):309-319. doi: 10.1080/10543406.2017.1293077. Epub 2017 Mar 21. J Biopharm Stat. 2018. PMID: 28323532 Free PMC article.

7

Stochastic inequality probabilities for adaptively randomized clinical trials.

Cook JD, Nadarajah S. Cook JD, et al. Biom J. 2006 Jun;48(3):356-65. doi: 10.1002/bimj.200510220. Biom J. 2006. PMID: 16845901

8

Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children.

Whelan HT, Cook JD, Amlie-Lefond CM, Hovinga CA, Chan AK, Ichord RN, Deveber GA, Thall PF. Whelan HT, et al. Among authors: cook jd. Stroke. 2008 Sep;39(9):2627-36. doi: 10.1161/STROKEAHA.107.510164. Epub 2008 Jul 10. Stroke. 2008. PMID: 18617665

9

Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. de Lima M, et al. Among authors: cook jd. Leukemia. 2008 Feb;22(2):258-64. doi: 10.1038/sj.leu.2405014. Epub 2007 Nov 8. Leukemia. 2008. PMID: 17989720 Clinical Trial.

10

A blueprint to deepen our understanding of the bidirectionality between sleep and emotional health.

Cook JD, Rumble ME. Cook JD, et al. Sleep. 2025 Nov 25:zsaf377. doi: 10.1093/sleep/zsaf377. Online ahead of print. Sleep. 2025. PMID: 41288600 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

344 results

Search Page

Filters